Its four approved medicines treat cystic fibrosis (CF), and one approved therapy ... This growth was attributed to its ex-Humira platform, a drug collection in the company’s pharmaceutical ...

This is despite the ongoing decline of long-time top-seller Humira (adalimumab), which ... and Vertex’s combination therapy for cystic fibrosis Trikafta (elexacaftor plus ivacaftor plus tezacaftor).

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

The company offers Humira, an injection for autoimmune and ... engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with ...

Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Stalled microbiomes: Cystic fibrosis disrupts early gut development in infants. ScienceDaily . Retrieved March 12, 2025 from www.sciencedaily.com / releases / 2025 / 02 / 250213143915.htm ...

GLENDALE, Ariz. -- While brushing off winter trade rumors and vowing to play "smarter" early in the season, Chicago White Sox center fielder Luis Robert Jr. reported to spring training Monday as ...